Sarepta Therapeutics Inc
NASDAQ:SRPT

Watchlist Manager
Sarepta Therapeutics Inc Logo
Sarepta Therapeutics Inc
NASDAQ:SRPT
Watchlist
Price: 21.5695 USD -1.01% Market Closed
Market Cap: $2.3B

Net Margin

-11.2%
Current
Improving
by 20.9%
vs 3-y average of -32.2%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-11.2%
=
Net Income
$-271.5m
/
Revenue
$2.4B

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-11.2%
=
Net Income
$-271.5m
/
Revenue
$2.4B

Peer Comparison

Country Company Market Cap Net
Margin
US
Sarepta Therapeutics Inc
NASDAQ:SRPT
2.3B USD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
385B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
184.4B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
169B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
118.3B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.1B USD
Loading...
AU
CSL Ltd
ASX:CSL
87B AUD
Loading...
NL
argenx SE
XBRU:ARGX
43.2B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
47.8B USD
Loading...

Market Distribution

Lower than 71% of companies in the United States of America
Percentile
29th
Based on 15 072 companies
29th percentile
-11.2%
Low
-4 418 600% — -9.6%
Typical Range
-9.6% — 11.3%
High
11.3% — 1 135 400%
Distribution Statistics
the United States of America
Min -4 418 600%
30th Percentile -9.6%
Median 3.1%
70th Percentile 11.3%
Max 1 135 400%

Sarepta Therapeutics Inc
Glance View

Sarepta Therapeutics Inc. is a company firmly rooted in the ambitious quest to change the lives of those grappling with rare genetic disorders, particularly focusing on Duchenne muscular dystrophy (DMD). The scientists and innovators at Sarepta are driven by their expertise in genetic medicine, utilizing cutting-edge technologies such as exon skipping, gene therapy, and RNA-targeted therapeutics to develop treatments that combat the underlying causes of these debilitating diseases. The company's journey is underscored by its commitment to not only advancing science but also accelerating the delivery of hope to patients and families affected by these life-limiting conditions. Central to Sarepta's business model is the commercialization of its approved therapies, alongside an expansive pipeline of potential treatments still in various stages of research and development. By prioritizing strategic partnerships and leveraging their robust intellectual property portfolio, Sarepta translates pioneering science into tangible healthcare solutions. Revenue is chiefly generated through the sales of its FDA-approved DMD treatments, capturing a market niche due to the lack of viable alternatives. As Sarepta looks toward future horizons, the company remains steadfast in its mission to scale new heights in genetic medicine, aiming to redefine the standard of care for rare neuromuscular diseases worldwide.

SRPT Intrinsic Value
58.7694 USD
Undervaluation 63%
Intrinsic Value
Price
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
-11.2%
=
Net Income
$-271.5m
/
Revenue
$2.4B
What is Sarepta Therapeutics Inc's current Net Margin?

The current Net Margin for Sarepta Therapeutics Inc is -11.2%, which is above its 3-year median of -32.2%.

How has Net Margin changed over time?

Over the last 3 years, Sarepta Therapeutics Inc’s Net Margin has increased from -81.7% to -11.2%. During this period, it reached a low of -114.3% on Mar 31, 2023 and a high of 12.4% on Dec 31, 2024.

Back to Top